ALUNG HEMOLUNG is an FDA cleared $ECCO_2R$ system focusing on 1) preventing invasive ventilation and 2) enabling application of lung protective ventilation strategies.

HEMOLUNG



- Intended for $ECCO_2R$ therapies of up to 5 days in adults at low blood flow rates of 350 – 550 mL/min
- Use cases: COPD, cystic fibrosis, severe asthma, bridge-to-transplant and any other where patient needs CO_2 removed directly from the blood
- Treatments aim to: 1) Prevent intubation and invasive ventilation when NIV is failing; 2) Enable application of lung protective ventilation strategies

Strengths

- Simpler system vs. ECMO that can be used in a variety of clinical settings
- World's first and only FDA cleared[1)] system for $ECCO_2R$ use
- Participation in a large VENT-AVOID trial for use of $ECCO_2R$ in AECOPD patients
- A recent trial showed evidence of benefit associated with $ECCO_2R$ in patients with AECOPD at risk of failing NIV. With commencement of $ECCO_2R$ improvements in respiratory acidosis, respiratory physiology and patient comfort were perceived

Weaknesses

- Pivotal REST trial showed no substantial benefits of $ECCO_2R$ in patients requiring mechanical ventilation for acute hypoxemic respiratory failure

ALUNG

- Founded in 1997 as a spin-off from the University of Pittsburgh
- Currently employs about 30 people
- Over 10+ institutional investors, including Philips
- ALung's main goal: to help prevent the "Downward Spiral of Respiratory Failure"



Source: TSN Business Intelligence, $ECCO_2R$ - Extracorporeal CO_2 Removal, AECOPD - Acute Exacerbations of Chronic Obstructive Pulmonary Disease, 1) FDA cleared through "De Novo" process